[1] Burdick JF, Vogelsang GB, Smith WJ, et al.Severe graft-versus-host disease in a liver-transplant recipient[J]. N Engl J Med,1988,318(11):689-691.
[2] Murali AR, Chandra S, Stewart Z, et al.Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management[J]. Transplantation,2016,100(12):2661-2670.
[3] Meng XQ, Chen XH, Sahebally Z, et al.Cytokines are early diagnostic biomarkers of graft-versus-host disease in liver recipients[J]. Hepatobiliary Pancreat Dis Int,2017, 16(1):45-51.
[4] Chen X, Meng X, Xu Y, et al.Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation[J]. Eur J Med Res,2016,21(1):38.
[5] Matsukuma KE, Wei D, Sun K, et al.Diagnosis and differential diagnosis of hepatic graft versus host disease(GVHD)[J]. J Gastrointest Oncol,2016,7(Suppl 1):S21-S31.
[6] Schulz JT 3rd, Sheridan RL. Severe desquamating disorder after liver transplant: toxic epidermal necrolysis or graft versus host disease?[J]. J Burns Wounds,2006,5:e1.
[7] Chaib E, Silva FD, Figueira ER, et al.Graft-versus-host disease after liver transplantation[J]. Clinics (Sao Paulo),2011,66(6):1115-1118.
[8] Schulman JM, Yoon C, Schwarz J, et al.Absence of peripheral blood chimerism in graft-vs-host disease follow-ing orthotopic liver transplantation: case report and review of the literature[J]. Int J Dermatol,2014,53(11):e492-e498.
[9] Akbulut S, Yilmaz M, Yilmaz S.Graft-versus-host disease after liver transplantation: a comprehensive literature review[J]. World J Gastroenterol,2012,18(37):5240-5248.
[10] Mawad R, Hsieh A, Damon L.Graft-versus-host disease presenting with pancytopenia after en bloc multiorgan transplantation: case report and literature review[J]. Transplant Proc,2009,41(10):4431-4433.
[11] Perkins JL, Neglia JP, Ramsay NK, et al.Successful bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation: long-term follow-up and outcome[J]. Bone Marrow Transplant,2001, 28(5):523-526.
[12] Hudspeth M, Turner A, Miller N, et al.Pancytopenia after allogeneic bone marrow transplant due to copper deficiency[J]. J Pediatr Hematol Oncol,2014,36(4):316-318.
[13] Rogulj IM, Deeg J, Lee SJ.Acute graft versus host disease after orthotopic liver transplantation[J]. J Hematol Oncol,2012,5:50.
[14] Shimata K, Sakamoto R, Anan T, et al.Fatal graft-versus-host disease after living-donor liver transplantation from an HLA-DR-mismatched donor[J]. Pediatr Transplant,2017,21(7).doi: 10.1111/petr.13039.
[15] Uchiyama H, Kayashima H, Matono R, et al.Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome[J]. Clin Transplant,2012,26(5):E522-E529.
[16] Ohe H, Hoshino J, Ozawa M.Factors affecting outcomes of liver transplantation: an analysis of OPTN/UNOS database[J]. Clin Transpl,2011:39-53.
[17] Kamei H, Oike F, Fujimoto Y, et al.Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way HLA matching[J]. Liver Transpl,2006, 12(1):140-145.
[18] Elfeki MA, Pungpapong S, Genco PV, et al.Graft-versus-host disease after orthotopic liver transplantation: multivariate analysis of risk factors[J]. Clin Transplant,2015, 29(12):1063-1066.
[19] Zhang C, Yang G, Ling Y, et al.Graft versus host disease following liver transplantation: A case report[J]. Exp Ther Med,2014,8(4):1164-1166.
[20] Chan EY, Larson AM, Gernsheimer TB, et al.Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients[J]. Liver Transpl,2007,13(4):516-522.
[21] Rai V, Dietz NE, Agrawal DK.Immunological basis for treatment of graft versus host disease after liver transplant[J]. Expert Rev Clin Immunol,2016,12(5):583-593.
[22] Jeanmonod P, Hubbuch M, Grunhage F, et al.Graft-versus-host disease or toxic epidermal necrolysis: diagnostic dilemma after liver transplantation[J]. Transpl Infect Dis,2012,14(4):422-426.
[23] Grosskreutz C, Gudzowaty O, Shi P, et al.Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation[J]. Am J Hematol,2008,83(7):599-601.
[24] Mousavi SA, Javadimoghadam M, Ghavamzadeh A, et al.The relationship between STR-PCR chimerism analysis and chronic GvHD following hematopoietic stem cell transplantation[J]. Int J Hematol Oncol Stem Cell Res,2017,11(1):24-29.
[25] Soejima Y, Shimada M, Suehiro T, et al.Graft-versus-host disease following living donor liver transplantation[J]. Liver Transpl,2004,10(3):460-464.
[26] Kuball J, Theobald M, Ferreira EA, et al.Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions[J]. Transplantation,2004,78(12):1774-1779.
[27] Thin L, Macquillan G, Adams L, et al.Acute graft-versus-host disease after liver transplant: novel use of eta-nercept and the role of tumor necrosis factor alpha inhibitors[J]. Liver Transpl,2009,15(4):421-426.
[28] Piton G, Larosa F, Minello A, et al.Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report[J]. Liver Transpl,2009,15(7):682-685.
[29] Trounson A, Thakar RG, Lomax G, et al.Clinical trials for stem cell therapies[J]. BMC Med,2011,9:52.
[30] Chen W, Li M, Li Z, et al.CXCR4-transduced me-senchymal stem cells protect mice against graft-versus-host disease[J]. Immunol Lett,2012,143(2):161-169.
[31] Ringdén O, Erkers T, Nava S, et al.Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease[J]. Stem Cells,2013,31(3):592-601.
